Table 1 Comparison of characteristics of AF ablated versus AF untreated populations: Total sample and propensity-matched groups
Variables | Total sample (N = 276) | Propensity-matched sample (N = 68) | |||||
|---|---|---|---|---|---|---|---|
AF with ablation (N = 42) | AF without ablation (N = 234) | P value | AF with ablation (N = 34) | AF without ablation (N = 34) | P value | ||
Age (mean ± SD) | 73.50 ± 2.44 | 74.89 ± 2.96 | 0.020 | 73.74 ± 2.50 | 74.15 ± 2.79 | 0.524 | |
Male(n) | 26 | 133 | 0.541 | 21 | 19 | 0.622 | |
BMI | 22.10 ± 3.13 | 21.96 ± 1.91 | 0.780 | 21.93 ± 3.01 | 21.43 ± 3.19 | 0.510 | |
Smoking history(n) | 15 | 49 | 0.037 | 11 | 12 | 0.798 | |
Diabetes (n) | 3 | 25 | 0.484 | 3 | 1 | 0.303 | |
Hypertension (n) | 23 | 87 | 0.032 | 16 | 15 | 0.808 | |
LVEF | 0.633 ± 0.860 | 0.635 ± 0.740 | 0.864 | 0.632 ± 0.088 | 0.654 ± 0.070 | 0.261 | |
NYHA IV (n) | 4 | 23 | 0.951 | ||||
LVDD (mm) | 52.98 ± 4.62 | 54.78 ± 6.04 | 0.030 | 53.19 ± 4.44 | 53.34 ± 4.84 | 0.858 | |
LA diameter (mm) | 39.26 ± 9.13 | 39.39 ± 8.88 | 0.926 | 39.07 ± 8.88 | 38.86 ± 8.76 | 0.923 | |
AF duration (years) | 5.24 ± 2.75 | 9.95 ± 4.48 | 0.000 | 5.91 ± 2.58 | 5.18 ± 3.42 | 0.320 | |
Serum creatinine (umol/L) | 97.75 ± 22.07 | 96.69 ± 22.21 | 0.777 | 95.58 ± 22.80 | 94.22 ± 21.74 | 0.801 | |
COPD(n) | 2 | 4 | 0.212 | 1 | 0 | 0.314 | |
Severe pulmonary hypertension (n) | 7 | 47 | 0.607 | 7 | 3 | 0.171 | |
Stroke/TIA(n) | 8 | 23 | 0–081 | 7 | 4 | 0.323 | |
CAD(n) | 5 | 41 | 0.607 | 5 | 4 | 0.720 | |
liver dysfunction (n) | 3 | 3 | 0.016 | 1 | 0 | 0.314 | |
Number of replacement valves (n) | Double | 19 | 109 | 0.872 | 17 | 19 | 0.627 |
Single | 23 | 125 | 17 | 15 | |||